Screening of Human Epidermal Growth Factor Receptor 2 (HER2) Extracellular Domain for Potential Epitopes by Using Immuno-informatics Tools

被引:0
|
作者
Odhar, Hasanain Abdulhameed [1 ]
Ahjel, Salam Waheed [1 ]
Odhar, Zanan Abdulhameed [2 ]
Humadi, Suhad Sami [1 ]
Rayshan, Ali Mahmood [1 ]
Hashim, Ahmed Fadhil [1 ]
机构
[1] Al Zahrawi Univ Coll, Dept Pharm, Karbala, Iraq
[2] Minist Hlth, Baghdad, Iraq
关键词
Breast cancer; HER2; immunotherapy; epitope; peptide vaccine; PREDICTION;
D O I
10.9734/JPRI/2021/v33i22A31383
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The human epidermal growth factor receptor 2 (HER2) is a well-studied oncoprotein that is overexpressed in a considerable proportion of breast cancer patients. The increased expression of this tyrosine kinase receptor is usually associated with poor clinical prognosis in female patients with breast cancer. In these patients, specific response of immune system against HER2 had been observed. This suggests that immunotherapy approaches can be employed for enhancing the response of tumor infiltrating lymphocytes against HER2 in susceptible tumor microenvironment. In this regard, peptide vaccines are considered one of the most affordable immunotherapy modalities due to their low production cost and long-term effect. For this purpose, we have screened the extracellular domain of HER2 crystal for potential B-cells and T-cells epitopes by using different immuno-informatics tools. The output peptides were then refined and filtered according to their antigenicity, allergenicity and vulnerability to selected proteases. Here, we present multiple B-cells and T-cells epitope candidates against HER2 extracellular domain with high antigenicity, low allergenicity and good resistance for selected proteolytic enzymes. These filtered epitopes can be used for design and construction of anti-HER2 peptide vaccine for potential use in HER2 positive breast cancer patients. Additionally, the sequence of linear B-cells epitopes can be used for the design of monoclonal antibody variable region against HER2 extracellular domain.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [41] Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
    Kim, Min Chong
    Kang, Su Hwan
    Choi, Jung Eun
    Bae, Young Kyung
    JOURNAL OF BREAST CANCER, 2020, 23 (05) : 484 - 497
  • [42] A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
    Nixon, N. A.
    Hannouf, M. B.
    Verma, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 89 : 72 - 81
  • [43] Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
    Mudgal, Shikha
    Paul, Pranoy
    Ravi, Bina
    Agrawal, Shruti
    Kalra, Arnav
    Rao, Shalinee
    Chowdhury, Nilotpal
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [44] SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors
    Qu, D.
    Yan, A.
    Zhang, J. S.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2017, 28 (02) : 111 - 132
  • [45] ANALYSIS OF F HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2/NEU) EXPRESSION IN GASTRIC ADENOCARCINOMA
    Umar, Nadia
    Shad, Waqar
    Irfan, Maria
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (06): : 12697 - 12700
  • [46] A human epidermal growth factor receptor 3 (HER3)-binding nanoparticle targets and kills Herceptin®-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    Sims, J. D.
    Taguaim, M.
    Hanson, C.
    Cui, X.
    Medina-Kauwe, L. K.
    CANCER RESEARCH, 2013, 73
  • [48] Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial.
    Adenis, A
    Aguilar, EA
    Robin, YM
    Miquel, R
    Penault-Llorca, F
    Castañón, C
    Queralt, B
    Eggleton, SP
    van den Berg, N
    Wilke, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 278S - 278S
  • [49] Human Epidermal Growth Factor Receptor 2 (HER2) Extracellular Domain Levels Are Associated with Progression-Free Survival in Patients with HER2-Positive Metastatic Breast Cancer Receiving Lapatinib Monotherapy
    Lipton, Allan
    Leitzel, Kim
    Ali, Suhail M.
    Carney, Walter
    Platek, Greg
    Steplewski, Klaudia
    Westlund, Ron
    Gagnon, Robert
    Martin, Anne-Marie
    Maltzman, Julie
    CANCER, 2011, 117 (21) : 5013 - 5020
  • [50] Human epidermal growth factor receptor 2/3 (HER2/HER3) expression in higher-grade meningioma
    Mair, Maximilian
    Tomasich, Erwin
    Paiato, Christina
    Widhalm, Georg
    Eckert, Franziska
    Sahm, Felix
    Hainfellner, Johannes A.
    Berghoff, Anna Sophie
    Preusser, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)